Safety data sheet. GHS / OSHA HCS 2012 format, 16 sections. Issued by Epic Peptides Lab for the catalogue items listed in Section 1.

Epic Peptides Lab

Safety data sheet · lyophilized powder, vial

Epic Peptides Lab · USA

Document number: PL-SDS-162
Revision: 1.0 · 2026-10-03

Tesamorelin

lyophilized powder, vial

WARNING

1Identification

Product Identifier

Tesamorelin

Document Number

PL-SDS-162

Catalogue Items Covered

Id
1942
Name
Tesamorelin 10mg
Sku
PL-TESA-10MG-VIAL

Recommended Use

Laboratory research use by trained personnel.

Restrictions On Use

Not for human or veterinary use.

Supplier / Distributor

Epic Peptides Lab, USA

Telephone

+1 (787) 468-5291

info@epicpeptideslab.com

2Hazard(s) identification

Classification

Reproductive toxicity — Category 2 — H361

Label Elements

Pictograms: GHS08
Signal: Warning
Hazard statements: H361 Suspected of damaging fertility or the unborn child.
Precautionary statements: P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P280 Wear protective gloves, protective clothing and eye protection.

P308+P313 IF exposed or concerned: Get medical advice/attention.

P405 Store locked up.

P501 Dispose of contents and container to an approved waste disposal plant in accordance with local, state and federal regulations.

Signal Word

Warning

Other Hazards

No data available.

3Composition / information on ingredients

Description

Lyophilized (freeze-dried) powder or cake in a sealed glass vial with a rubber stopper and aluminium crimp cap.

Composition

Name
Tesamorelin
Full
Tesamorelin (trans-3-hexenoyl-GHRH(1-44)-NH2)
Cas
218949-48-5
Formula
C221H366N72O67S
Conc
≥ 95% (dry basis, as supplied)
Qty
10 mg per vial
Hazards
- Reproductive toxicity — Category 2 — H361

4First-aid measures

First Aid Measures

Inhalation: Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor.
Skin: Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice.
Eyes: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice.
Ingestion: Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell.
General: If exposed or concerned, get medical advice. Show this safety data sheet to the doctor. Pregnant or nursing laboratory staff should avoid exposure.

Most Important Symptoms And Effects

No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

Likely Routes Of Exposure

Inhalation of dust, skin and eye contact when the vial is opened or the powder is weighed; ingestion through contaminated hands; accidental injection when reconstituted solutions are drawn into syringes.

5Fire-fighting measures

Fire Fighting Information: Combustible organic solid; finely divided powder may form dust clouds. Not flammable in the quantities supplied.

6Accidental release measures

Spill And Clean Up Procedures: Avoid dust formation. Dampen spilled powder with water, wipe up with absorbent material, place in a sealed container for disposal and clean the area with water and detergent.

7Handling and storage

Safe Handling: Open vials only in a clean area. Avoid generating or inhaling dust; weigh or reconstitute inside a ventilated enclosure when the full contents are handled as a dry powder. Reconstitute by adding diluent slowly to the vial wall; do not shake. Wash hands after handling.
Safe Storage: Store the sealed vial at the temperature stated in Section 9 (typically −20 °C for peptides, 2–8 °C for proteins), desiccated and protected from light. Allow the vial to reach room temperature before opening to avoid condensation. Reconstituted solutions: 2–8 °C, protected from light; use within the period established by your laboratory.
Storage Temperature: −20 °C (sealed vial), desiccated and protected from light; 2–8 °C acceptable for short periods
Incompatible Materials: No further relevant information available (Cayman); generic: strong oxidizing agents, strong acids/bases

8Exposure controls / personal protection

Occupational Exposure Limits: No data available.
Exposure Controls And PPE: No data available.

9Physical and chemical properties

Physical State

Solid

Appearance

White to off-white lyophilized powder

Properties

Odor: Characteristic (Cayman); threshold not determined
Ph: Not applicable (solid); aqueous solutions typically pH 4–7
Melting: Undetermined
Boiling: Undetermined
Flash: Not applicable (non-flammable solid); combustible organic material
Vapour: Negligible (solid)
Density: No data available (bulk density of lyophilized cake is low)
Solubility: PBS pH 7.2: sparingly soluble, 1-10 mg/ml (Cayman product page); water solubility not determined in SDS
Logp: No data available
Decomp: No data available; peptides decompose above about 200 °C
Other: Not flammable. CAS 218949-48-5; C221H366N72O67S, MW 5135.9 (free peptide); trans-3-hexenoyl-GHRH(1-44)-NH2 (TH9507); Cayman acetate salt C221H366N72O67S • xC2H4O2; contains one Met (oxidation-prone)

10Stability and reactivity

Stability And Reactivity

Reactivity: No dangerous reactions known; no decomposition if used according to specifications (Cayman)
Incompatible: No further relevant information available (Cayman); generic: strong oxidizing agents, strong acids/bases
Decomposition: No dangerous decomposition products known (Cayman); combustion yields carbon oxides, nitrogen oxides, sulfur oxides
Conditions To Avoid: No further relevant information available; store -20 °C desiccated and dark (lyophilized); reconstituted drug product must be used immediately per label

Conditions To Avoid

No data available.

Incompatible Materials

No data available.

11Toxicological information

Toxicological Information: Acute toxicity, oral
No data available

Acute toxicity, dermal
No data available

Acute toxicity, inhalation
No data available

Skin corrosion/irritation
No irritant effect (Cayman)

Serious eye damage/irritation
No irritating effect (Cayman)

Respiratory or skin sensitisation
No sensitizing effects known (Cayman). Clinical: hypersensitivity reactions and injection-site reactions reported with Egrifta

Germ cell mutagenicity
No data available

Carcinogenicity
Not listed by IARC, NTP or OSHA (Cayman)

Reproductive toxicity
No data available in SDS. Egrifta prescribing information: contraindicated in pregnancy (formerly Pregnancy Category X) and developmental toxicity was observed in animal studies - reproductive-toxicity concern for a GHRH-analogue hormone (see notes)

STOT, single exposure
No data available

STOT, repeated exposure
No data available

Aspiration hazard
No data available
Routes Of Exposure: Inhalation of dust, skin and eye contact when the vial is opened or the powder is weighed; ingestion through contaminated hands; accidental injection when reconstituted solutions are drawn into syringes.
Symptoms: No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

12Ecological information

Ecological Information: Cayman: Water hazard class 1 (self-assessment), slightly hazardous for water; no aquatic toxicity, persistence or bioaccumulation data.

13Disposal considerations

Disposal Guidance: No data available.

14Transport information

Transport Classification

Note: Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used.

15Regulatory information

Regulatory Information

Tsca: Substance is not listed (Cayman)
Carcinogen Listings: Not listed by IARC, NTP, OSHA or EPA
Dea: Not a controlled substance
Other: FDA-approved prescription drug (Egrifta / Egrifta SV / Egrifta WR, Theratechnologies). WADA remark: tesamorelin is explicitly named on the WADA Prohibited List (S2 Peptide hormones, growth factors - GHRH and its analogues).

Carcinogen Listings

No data available.

16Other information

Revision: October 3, 2026
Sources Consulted: Cayman Chemical

Cayman Chemical product page
Confidence: medium
Additional Information: GHRH analogue. WADA Prohibited List class S2.

Back to SDS list